Scarica l'app Stockscreener
2.20
1.85%
0.04
Dopo l'orario di chiusura:
2.18
-0.02
-0.91%
Nrx Pharmaceuticals Inc Borsa (NRXP) Ultime notizie
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com
NRx Pharmaceuticals, Inc. (NRXPW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo! Finance Canada
NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network - MSN
NRX Pharmaceuticals (HAM:B1Q) PB Ratio : (As of Mar. 31, 2026) - GuruFocus
NRx Pharmaceuticals, Inc. (NRXPW) stock price, news, quote and history - Yahoo Finance Singapore
Hedge Fund Bets: Is NRx Pharmaceuticals Inc backed by strong institutional buyingEarnings Overview Report & Smart Money Movement Tracker - baoquankhu1.vn
AI-Powered 'Depression Thermometer' to Aid Interventional Psychiatry Network - National Today
AI-Powered “Depression Thermometer” to Aid Interventional Psychiatry Network via Strategic Partnership with Emobot for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network - Bitget
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary, Announces Strategic Partnership with Emobot - citybiz
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered 'Depression Thermometer” Across its Interventional Psychiatry Network - The Manila Times
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network - The Globe and Mail
NRx says FDA will review NRX-100 without new trials - MSN
NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability - simplywall.st
Nrx Pharmaceuticals’ Earnings Call Signals High‑Stakes Progress - The Globe and Mail
Published on: 2026-03-29 11:07:47 - baoquankhu1.vn
NRX Pharmaceuticals (HAM:B1Q) Cyclically Adjusted PS Ratio : (As of Apr. 01, 2026) - GuruFocus
Can NRx Pharmaceuticals Inc scale operations efficiently2026 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
NRX Pharmaceuticals (HAM:B1Q) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Insider Buy: Is NRx Pharmaceuticals Inc a stock for growth or value investors2026 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101 - Insider Monkey
NRx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nrx Pharmaceuticals: Extensive Clinical, Regulatory, and Financial Risks Make Shares Highly Speculative - tipranks.com
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
NRx Pharmaceuticals, Inc. 8-K Filing Details: Company Information, Stock, and Warrants Registered on NASDAQ – March 2026 - Minichart
NRx Pharmaceuticals Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - Investing News Network
NRx Pharmaceuticals Stockholders Approve Incentive Plan Amendment - TipRanks
NRx Pharmaceuticals stock rating reiterated at Buy by BTIG on FDA progress - Investing.com Australia
NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate - Stock Titan
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
NRx Says FDA Finds No Bioequivalence Issues in Ketamine Filing - MyChesCo
NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from BTIG Research - MarketBeat
NRx Pharmaceuticals (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress - The Globe and Mail
NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Beats Expectations By $0.28 EPS - MarketBeat
NRx Pharmaceuticals Announces Full-Year 2025 Results with Commercial and Regulatory Updates - citybiz
NRX Pharmaceuticals’ 2025 Q4 Earnings Call: Shifting Commercialization Strategy and NDA Timeline Clash With Prior Statements - Bitget
NRX Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: NRX Pharmaceuticals Q4 2025 shows operational strides By Investing.com - Investing.com India
NRXP: Reduced losses, revenue growth, and key drug milestones position for profitability in 2026 - TradingView
NRx Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: NRX Pharmaceuticals Q4 2025 shows operational strides - Investing.com
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - The Manila Times
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
NRx Says FDA Will Review NRX-100 Without New Trials - MyChesCo
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead - marketbeat.com
NRX Pharmaceuticals, Inc. 2025 Annual Report: Financials, Risk Factors, and Nasdaq Listing Overview - Minichart
NRXP SEC FilingsNrx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):